Celcuity Inc. (NASDAQ: CELC) is a Healthcare company (Biotechnology) with a market capitalization of $2.8B. The Maz Rating grades it against the other companies in its sector.
Celcuity Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Celcuity Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -1522.5%, return on invested capital of -35.7% and a free cash flow yield of -7.6%. On the balance sheet: a debt-to-equity ratio of -10.20 and a current ratio of 14.62. Over the past 52 weeks the share price ranged from $53.54 to $151.02, with a beta of 0.16.
Celcuity Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 13 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Celcuity Inc. (CELC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 18.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.3% / 30% · Interest income / Revenue 667300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 18.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 667300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 18.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 667300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 78.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 81.6% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 667300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 103.7% / 33.33% · (Cash+ST Inv) / Total Assets 88.4% / 33.33% · (Cash+Recv) / Total Assets 88.4% / 33.33% · Interest income / Revenue 667300000.0% / 5% | Fail |
No. As of September 2026, Celcuity Inc. (CELC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Celcuity Inc. is over the AAOIFI limit on Interest income / Revenue.
About 667300000.0% of each dividend: Celcuity Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.